Aastrom's heart failure drug enters midstage development

04/8/2013 | Pharmaceutical Business Review Online

Aastrom Biosciences has started recruiting patients for a Phase IIb trial that will assess the safety and efficacy of its experimental drug Ixmyelocel-T in people with advanced heart failure due to ischemic dilated cardiomyopathy. The randomized, double-blind trial will involve 108 patients.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ